Drug Research

As anticipated, Congress swiftly reauthorized four important user fee programmes as part of a bill that was essential to passing in order to continue funding the federal government for another two months. The October 1 deadline for approving a...

Gene therapy remains a topic of fascination to biopharmaceutical dealmakers despite safety worries and opposition from drug regulators, as seen by a recent flurry of deals. Eli Lilly agreed to purchase Akouos, a Boston-based company that develops gene therapies for...

One of the most difficult medical research findings, drug distribution still faces a lot of challenges, including surviving the acidic parts of the stomach, digestive enzymes, and most significantly, the mucus barrier that surrounds the digestive canal. Scientists at...

Deals can be just as significant in the drug development industry as scientific advancements. Without mergers and acquisitions, many of today's most significant pharmaceuticals—from the anti-inflammatory Humira to the life-saving cancer medication Keytruda—might not have come to be. Pharmaceutical M&A...

On October 28th, an advisory board to the European Medicines Agency advised restricting the use of a class of medications for inflammatory diseases due to a known association with side effects like cancer and heart attacks. The group recommended limiting...

A new type of COVID-19 vaccination that is provided via inhalation rather than injection was this week introduced in Shanghai, the commercial city of China, in what is thought to be a first for the world. In September, Chinese authorities...

The necessity to update and alter the FDA's now-contentious rapid approval strategy is highlighted by the protracted, complicated FDA process to discontinue commercialization of medications that do not demonstrate safety and efficacy in mandated post-approval confirmatory studies. Over the...